Healthcare Industry News: Non-Small Cell Lung Cancer
News Release - August 5, 2008
New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment TimesFirst Patients Treated Using Next Generation CyberKnife System at Oklahoma CyberKnife Center
SUNNYVALE, Calif., Aug. 5 (HSMN NewsFeed) -- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today that the first patients were treated using the next generation CyberKnife® Robotic Radiosurgery System that was recently installed at the Oklahoma CyberKnife, LLC in Tulsa, OK. The next generation CyberKnife System, which features new technologies and system upgrades announced at the 2007 American Society for Therapeutic Radiology and Oncology Annual Meeting, is capable of delivering state-of-the-art radiosurgery with significantly reduced treatment planning and delivery times.
Treatment results on the Oklahoma CyberKnife, LLC's first day were ground-breaking. While treatment times will vary based upon case complexity and type of cancer, the first patient treated for an intracranial lesion was completed in only 16 minutes. The next patient, treated for Non-Small Cell Lung Cancer, required only 27 minutes of treatment time.
Incorporating all of the newest enhancements, the next generation CyberKnife System achieved a considerable reduction in treatment times. Using the latest advancement in treatment planning, Sequential Optimization enabled treatment plans to be developed in as little as 15 minutes. With the new 800 monitor unit/minute linear accelerator treatment times were reduced with a 30 percent faster rate of dose delivery as compared to previous systems. Further, the recently launched Iris(TM) Variable Aperture Collimator enabled very conformal, multi-collimator treatments to be rapidly delivered to even the most complex targets. And with the new Optimized Path Traversal feature, treatment times were further reduced with more efficient robotic motion.
"This new CyberKnife System configuration now allows us to deliver radiosurgical quality treatments almost as fast as radiation therapy," said Greg Spurlock, chief operating officer of US Radiosurgery, the managing partner of Oklahoma CyberKnife, LLC. "With the CyberKnife System however, the entire course of therapy is completed in one to five treatments. Compared to the two month regimen of 30 to 40 treatments required with conventional radiation therapy, the CyberKnife System clearly benefits both the patient and the provider."
Lung cancer treatments with the CyberKnife System are typically completed in three sessions. The net result of the introduction of these new technologies is to deliver an entire course of radiosurgery in about 1.5 hours. The shorter treatment regimen of CyberKnife radiosurgery not only improves patients' quality of life by not requiring a prolonged course of daily treatment visits, it can also lighten the burden on healthcare providers, saving time, expense and overhead, while also providing for significantly greater patient throughput.
"For all radiation delivery systems, plan quality and treatment time have historically had an inverse relationship," said Eric P. Lindquist, senior vice president and chief marketing officer of Accuray Incorporated. "While other radiosurgery systems actively promote fast treatment times, plan quality often suffers accordingly. Integrating all of the latest technologies, CyberKnife treatment times can now be reduced considerably with absolutely no sacrifice in treatment quality."
While Oklahoma CyberKnife, LLC purchased its CyberKnife System with all the next generation upgrades included, those same upgrades were made available to existing customers through Accuray's Diamond Elite Service Agreement, which enables customers to choose the right upgrades and payment plans to fit their technology strategy.
"We are very pleased with this new ability to efficiently deliver the highest quality, state-of-the-art radiosurgery to the Tulsa community," said Spurlock.
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non- invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY ), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 130 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com .
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, clinical studies, regulatory review and approval, and market acceptance and commercialization of products and services are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the year ended June 30, 2007 as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAccuray Unveils VOLO(TM) Ultra, the Latest Innovation for the Radixact(R) System, at ASTRO 2021
C-RAD and Accuray Sign Agreement to Enhance Radixact(R) System Breast Cancer Treatment Capabilities
French Hospital Network Unicancer Acquires Multiple Accuray Radixact(R) Systems with the ClearRT(TM) Helical Fan-Beam kVCT Imaging and Synchrony(R) Technologies